Downregulation of Opa1 and Marf does affect type II NB numbers but affect differentiated cells in lineage. by Dnyanesh Dubal (12085942)

Expression of mRFP does not perturb the severity of <i>opa1</i> RNAi and <i>marf</i> RNAi phenotypes. by Dnyanesh Dubal (12085942)

Drp1^SD overexpression in <i>opa1</i> RNAi and <i>marf</i> RNAi expressing type II NB lineages suppresses the differentiation defect. by Dnyanesh Dubal (12085942)

Opa1 and Marf depletion leads to fragmented mitochondria and overexpression of Drp1^SD leads to clustered mitochondria in type II NBs. by Dnyanesh Dubal (12085942)

CXCL10 production is enhanced in the setting of HIV and HBV co-infection in vitro and decreased with the addition of antiretroviral agents efavirenz or raltegravir. by Kasha P. Singh (9354307)

The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages. by Manuela Mally (348810)

Compatible pollen triggers a decrease in S-RNase transcript levels by a post-transcriptional mechanism. by Bolin Liu (59887)

A hypoglycaemic <i>milieu</i> decreases NCS viability in a dose-dependent manner. by Shiva Mansouri (2838086)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

Resveratrol decreases CYP17A1 and CYP21A2 protein expression. by Nesa Marti (3851059)

“…<p>A. Gene expression profiling by qRT-PCR was performed for CYP17, CYP21 and their cofactor POR in H295R cells grown under normal conditions (GM), starvation conditions (SM), metformin (Met) (1mM) treatment and under resveratrol (RSV) (5<u>μM)</u> treatment. …”

BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

<i>SIRT6</i> Minor Allele Genotype Is Associated with >5-Year Decrease in Lifespan in an Aged Cohort by Mindi J. TenNapel (679433)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i>^<i>ECKO</i> mice and lesions in the retina of <i>Ccm2</i>^<i>ECKO</i> mice. by Jia Li (160557)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)